

## CDKN1A

**Reactivity:**Human Rat

**Tested applications:**WB IHC IP

**Recommended Dilution:**WB 1:500 - 1:2000 IHC 1:50 - 1:200 IP 1:20 - 1:50

**Calculated MW:**21kDa

**Observed MW:**Refer to Figures

**Immunogen:**

A synthetic peptide of human CDKN1A

**Storage Buffer:**

Store at -20. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

**Concentration:**

b

**Synonym:**

CDKN1A;CAP20;CDKN1;CIP1;MDA-6;P21;SDI1;WAF1;p21CIP1 ;Cyclin-dependent kinase inhibitor 1 ; p21;

**Catalog #:**A0319

**Antibody Type:**

Polyclonal Antibody

**Species:**Rabbit

**Gene ID:**1026

**Isotype:**IgG

**Swiss Prot:**P38936

**Purity:**Affinity purification

For research use only.

**Background:**

The tumor suppressor protein p21 Waf1/Cip1 acts as an inhibitor of cell cycle progression. It functions in stoichiometric relationships forming heterotrimeric complexes with cyclins and cyclin-dependent kinases. In association with CDK2 complexes, it serves to inhibit kinase activity and block progression through G1/S (1). However, p21 may also enhance assembly and activity in complexes of CDK4 or CDK6 and cyclin D (2). The carboxy-terminal region of p21 is sufficient to bind and inhibit PCNA, a subunit of DNA polymerase, and may coordinate DNA replication with cell cycle progression (3). Upon UV damage or during cell cycle stages when cdc2/cyclin B or CDK2/cyclin A is active, p53 is phosphorylated and upregulates p21 transcription via a p53-responsive element (4). Protein levels of p21 are downregulated through ubiquitination and proteasomal degradation (5).

**To place an order, please [Click HERE](#).**